DUBLIN--(BUSINESS WIRE)--The "Metabolic Disorders - Disease & Epidemiology Overview" report from Decision Resources Group has been added to ResearchAndMarkets.com's offering.
The Metabolic Disorders Disease & Epidemiology Overview report provides disease market overviews and global epidemiology overviews for 10 indications in the Metabolic Disorders therapy area:
Acromegaly, Amyloidosis, Dyslipidemia, Gout, Non-alcoholic Steatohepatitis, Obesity/Overweight, Osteoporosis, Primary Biliary Cholangitis, Type 1 Diabetes and Type 2 Diabetes Disease. This report provides a disease market overview for each indication and global epidemiology overviews for each indication.
The disease market overviews include information such as market size forecasts, prevailing treatment trend analysis and predictions, key areas of unmet need, current and emerging therapies, physician (KOL) insights, clinical pipeline analysis, and more, for each indication. The global epidemiology overviews provide insights including global diagnosed prevalence, diagnosed prevalence by region, 10-year diagnosed prevalence growth forecast, relative sizes of the factors contributing to the trend in prevalent cases, and more, for each indication.
Key Topics Covered:
- About the Analyst
- About the analyst's Epidemiology
- Disease Landscape and Insight Overview
- Epidemiology Overview
Companies Mentioned
- Pfizer
- Alnylam
- Ionis/Akcea
- Takeda
- Janssen and Genmab
-
GSK
For more information about this report visit https://www.researchandmarkets.com/research/n92dn3/metabolic?w=4
